Understanding STARP1: A Potential Drug Target and Biomarker (G6771)

Target Name: STARP1

NCBI ID: G6771

STARP1

Other Name(s): STARD1P1 | steroidogenic acute regulatory protein pseudogene 1 | Steroidogenic acute regulatory protein pseudogene 1

Understanding STARP1: A Potential Drug Target and Biomarker

STARP1 (STARD1P1) is a protein that is expressed in various tissues of the body, including the brain, heart, and kidneys. It is a member of the STAR family of proteins, which are known for their role in regulating cell signaling pathways. STARP1 has been identified as a potential drug target or biomarker due to its involvement in several cellular processes that are associated with a variety of diseases, including cancer, neurodegenerative diseases, and autoimmune disorders.

The STAR family of proteins was identified in the 1990s as a key regulator of cell signaling pathways. The STAR family includes several different proteins, including STARP1, STARP2, STARP3, and STARP4, which are expressed in various tissues of the body. These proteins share a conserved catalytic core and a common catalytic domain, which is responsible for their unique catalytic activity.

STARP1 is a 21-kDa protein that is expressed in the brain, heart, and kidneys. It is involved in several cellular processes, including cell signaling, DNA replication, and protein synthesis. STARP1 has been shown to play a role in regulating the activity of several signaling pathways, including the PI3K/Akt signaling pathway, the TGF-β signaling pathway, and the NF-kappa-B signaling pathway.

In addition to its role in cell signaling, STARP1 is also a potential drug target or biomarker due to its involvement in several diseases. For example, STARP1 has been shown to be overexpressed in several types of cancer, including breast, ovarian, and colorectal cancer. This suggests that targeting STARP1 may be a promising strategy for the development of new cancer therapies.

STARP1 has also been identified as a potential biomarker for several neurodegenerative diseases, including Alzheimer's disease and Parkinson's disease. These conditions are characterized by the progressive loss of brain cells and the development of characteristic symptoms, such as memory loss, tremors, and difficulty with movement. By targeting STARP1, researchers may be able to develop new diagnostic tools and therapies for these conditions.

In addition to its potential role in disease, STARP1 has also been shown to be involved in several normal physiological processes in the body. For example, STARP1 is involved in regulating the production of flagellin, a protein that is essential for cell movement in eukaryotic cells. This suggests that targeting STARP1 may be a promising strategy for the development of new therapies for a variety of conditions, including cancer, neurodegenerative diseases, and autoimmune disorders.

In conclusion, STARP1 is a protein that is involved in several cellular processes that are important for normal physiological function and the development of disease. As a potential drug target or biomarker, STARP1 is a promising target for the development of new therapies for a variety of conditions. Further research is needed to fully understand the role of STARP1 in cell signaling and disease, and to develop effective therapies based on this protein.

Protein Name: Steroidogenic Acute Regulatory Protein Pseudogene 1

The "STARP1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about STARP1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets